Peptide Clinical Trial Design

Clinical trial design for peptide drugs requires consideration of pharmacokinetic properties (short half-life, rapid absorption), route of administration (SC, IV, IM, nasal), immunogenicity risk, and patient populations. Peptides occupy a unique position between small molecules and biologics, with specific trial design requirements.

Trial Design Framework

ICH E6(R2) Good Clinical Practice

Principle	Application to Peptides
Scientific soundness	PK/PD-guided design
Ethical conduct	Informed consent, risk minimization
Data integrity	Electronic data capture, audit trails
Patient safety	DSMB, stopping rules

Phases

Phase	Objective	Typical n	Duration
Phase I	Safety, tolerability, PK	20–100	6–12 months
Phase II	Dose-finding, efficacy signals	100–500	6–18 months
Phase III	Pivotal efficacy, safety	500–5000	1–3 years
Phase IV	Post-marketing, real-world	1000+	Ongoing

Phase I Design

Single Ascending Dose (SAD)

Element	Design
Population	Healthy volunteers or patients
Design	Open-label, dose-escalation
Dose levels	3–6 (3 patients/level minimum)
Escalation	3+3 or Bayesian optimal interval
Primary endpoint	Safety, tolerability
Secondary endpoint	PK parameters

Multiple Ascending Dose (MAD)

Element	Design
Population	Healthy volunteers or patients
Design	Open-label or randomized, dose-escalation
Dose levels	3–5
Duration	2–4 weeks per dose level
Primary endpoint	Safety, tolerability, PK steady-state
Secondary endpoint	PD biomarkers

Food Effect Study

Element	Design
Population	Healthy volunteers
Design	Randomized, crossover
Arms	Fasted vs fed (high-fat meal)
Primary endpoint	AUC, Cmax comparison
Statistical	Bioequivalence (80–125% CI)

Drug-Drug Interaction Study

Element	Design
Population	Healthy volunteers
Design	Crossover or parallel
Arms	Peptide alone, peptide + interacting drug, interacting drug alone
Primary endpoint	AUC, Cmax comparison
Statistical	Bioequivalence (80–125% CI)

Phase II Design

Dose-Ranging Study

Element	Design
Population	Target patient population
Design	Randomized, double-blind, placebo-controlled
Dose levels	3–4 doses + placebo
Primary endpoint	Efficacy (dose-response)
Secondary endpoint	Safety, PK/PD
Statistical	Emax modeling, MCP-Mod
Duration	12–26 weeks

Biomarker-Guided Design

Biomarker	Application	Measurement
HbA1c	Glycemic control	Blood draw
Body weight	Obesity	Scale
IGF-1	GH action	Blood draw
Glucose (CGM)	Glycemic variability	Continuous
LDL cholesterol	Lipid response	Blood draw
UACR	Nephropathy	Urine

Phase III Design

Pivotal Trial Design

Element	Design
Population	Target patient population (well-defined)
Design	Randomized, double-blind, active-controlled or placebo-controlled
Arms	Treatment, comparator, placebo (if ethical)
Primary endpoint	Clinically meaningful endpoint
Secondary endpoints	Multiple (pre-specified)
Statistical	Superiority or non-inferiority
Power	≥90% (typically)
Alpha	0.05 (two-sided)
Duration	26–52 weeks (minimum)

Non-Inferiority Design

Parameter	Specification
Non-inferiority margin	Pre-specified (clinically justified)
Per-protocol population	Primary analysis population
ITT population	Supportive analysis
Assay sensitivity	Must be demonstrated
Preservation of benefit	Must be shown

Superiority Design

Parameter	Specification
Effect size	Clinically meaningful difference
Power	≥90%
Alpha	0.05 (two-sided)
Multiplicity	Pre-specified adjustment (if multiple endpoints)

Endpoint Selection

Efficacy Endpoints

Indication	Primary Endpoint	Secondary Endpoints
Type 2 diabetes	HbA1c change	FPG, PPG, time in range
Obesity	% body weight change	Waist circumference, metabolic parameters
Acromegaly	IGF-1 normalization	GH levels, tumor size
EPP	Time to first pain after light exposure	Pain severity, quality of life
Heart failure	MACE, hospitalization	Quality of life, biomarkers
FSD	SFI change	Desire, arousal, satisfaction

Safety Endpoints

Category	Endpoint
Adverse events	Frequency, severity, causality
Laboratory safety	Chemistry, hematology, urinalysis
Vital signs	BP, HR, temperature
ECG	QTc prolongation, arrhythmia
Injection site	Reactions, nodules
Immunogenicity	ADA, NAb
Hypoglycemia	Documented episodes

Statistical Considerations

Sample Size Calculation

Factor	Consideration
Effect size	Clinically meaningful difference
Variability	Intra-subject CV (10–30% for peptides)
Power	≥90% (typically)
Alpha	0.05 (two-sided)
Dropout rate	15–25% (obesity trials higher)
Multiplicity	Adjustment for multiple comparisons

Analysis Populations

Population	Definition	Primary Use
ITT	All randomized patients	Primary analysis
mITT	All randomized, ≥1 dose, ≥1 post-baseline	Supportive
Per-protocol	ITT without major protocol violations	Sensitivity
Safety	All who received ≥1 dose	Safety

Missing Data Handling

Method	Application
LOCF	Not recommended (bias)
MMRM	Recommended for longitudinal data
Multiple imputation	Sensitivity analysis
Pattern-mixture models	Sensitivity analysis
Tipping point analysis	Sensitivity analysis

Patient Population

Inclusion Criteria (Typical)

Criterion	Type 2 Diabetes	Obesity	Acromegaly
Age	18–75 years	18–75 years	18–75 years
HbA1c	7.0–10.5%	N/A	N/A
BMI	N/A	≥30 or ≥27 + comorbidity	N/A
IGF-1	N/A	N/A	>ULN
Prior therapy	Metformin (≥3 months)	Lifestyle intervention	Surgery/radiation failed

Exclusion Criteria (Typical)

Criterion	Rationale
Type 1 diabetes	Wrong population
eGFR <30	Safety
Pancreatitis history	Safety
MTC/MEN 2 (GLP-1 RAs)	Contraindication
Pregnancy/lactation	Safety
Active malignancy	Safety
Severe GI disease	PK/absorption concerns
Smoking (inhaled peptides)	Contraindication

Immunogenicity Assessment

Assay Strategy

Assay	Purpose	Sensitivity
Screening ELISA	Detect ADA	≥5 ng/mL
Confirmatory ELISA	Confirm specificity	≥10 ng/mL
Titer assay	Quantify ADA	Dilution series
Neutralizing antibody	Functional impact	Cell-based assay

Immunogenicity Risk Factors

Factor	Risk Level	Mitigation
Peptide size	Larger = higher	Sequence optimization
Non-human sequence	Higher	Humanization
Aggregation	Higher	Formulation optimization
Route (SC > IV)	SC higher	Consider IV if needed
Dosing frequency	More frequent = higher	Long-acting formulation
Impurities	Higher	Purity optimization

Special Populations

Renal Impairment

eGFR	Study Design
60–89	No adjustment needed
30–59	Dedicated renal impairment study
<30	Dedicated severe renal impairment study
Dialysis	Dedicated end-stage study

Hepatic Impairment

Child-Pugh	Study Design
A (5–6)	No adjustment needed
B (7–9)	Dedicated hepatic impairment study
C (10–15)	Dedicated severe hepatic impairment study

Pediatric

Age Group	Study Design
Neonates	Only if justified by disease
Infants (1–23 months)	PK, safety
Children (2–11 years)	PK, efficacy (if applicable)
Adolescents (12–17 years)	Full efficacy trial

Geriatric

Consideration	Recommendation
Age range	≥65 years subgroup
Dose adjustment	Based on PK analysis
Safety monitoring	Enhanced monitoring
Polypharmacy	Drug interaction assessment

Regulatory Strategy

Pre-IND Meeting

Topic	Discussion
Nonclinical package	Completeness, adequacy
Clinical development plan	Design, endpoints
CMC requirements	Specifications
Special populations	Pediatric, renal

End-of-Phase II Meeting

Topic	Discussion
Phase III design	Pivotal trial strategy
Endpoints	Primary, secondary
Statistical analysis plan	Analysis details
Regulatory pathway	NDA vs BLA

Pre-NDA/BLA Meeting

Topic	Discussion
Clinical data package	Adequacy
CMC completeness	Gap assessment
Labeling	Draft labeling
Post-marketing requirements	Commitments

Data Management

EDC System Requirements

Requirement	Standard
21 CFR Part 11 compliance	Audit trails, electronic signatures
CDISC standards	SDTM, ADaM
Database lock	Pre-specified criteria
Data quality	Edit checks, queries

CDISC Standards

Standard	Application
SDTM	Study data tabulation
ADaM	Analysis data
SEND	Nonclinical data (if applicable)
Define-XML	Variable definitions

References

• Clinical Trials
• Peptide Clinical Dosing
• Peptide Pharmacokinetics
• Peptide Toxicology
• Peptide Bioanalysis